The Pulmonary Fibrosis Foundation (PFF) recently announced the opening of registration for an international conference aimed at educating the public and medical professionals on the causes, effects and treatment options for Pulmonary Fibrosis, titled PFF Summit 2015: From Bench to Bedside. The conference is scheduled to be held from November 12th to 14th at the JW Marriott in Washington DC. The France Foundation will provide CME (Continuing Medical Education) certificates at the conference for all professional medical attendees.
The aim of this conference is to educate medical professionals on the recent therapeutic trends in Pulmonary Fibrosis (PF), a fatal disease causing permanent scarring of the lungs, as well as new treatment options from research-based studies. Researchers interested in presenting a poster on their work at the conference I can begin submitting abstracts on June 1st.
In addition to offering continuing education to medial professionals who treat IPF, the conference will also bring together patients living with the disease along with their caregivers and supporters to discuss ways to improve lifestyle and increase patient lifespan. The conference will include a session of comprehensive and unrestricted discussion on the disease in general, which all attendees are invited to participate in. A separate session will be held for patients and caregivers to provide education and lifestyle tips for healthy living.
Some of the main topics to be addressed at the conference, which will include around 50 sessions in total, will include:
- The science of molecular and genetic biomarkers.
- Lung remodeling and regeneration.
- Patient-focused clinical trial endpoints.
- New treatment strategies.
- Patient goals and priorities for PF research.
- Pulmonary rehabilitation and oxygen therapy.
- Issues faced by individuals with advanced disease.
- Patient and caregiver coping skills.
Dr. Daniel M. Rose, MD, PFF CEO, stated, “The Foundation is honored to once again offer this exceptional opportunity for the pulmonary fibrosis community. The presentations will review the latest research and discuss important clinical and therapeutic issues. We developed this unique conference in order that health care providers can share best practices so that they may improve patient care, provide a forum in which attendees can engage in meaningful dialogue, and create an environment which will serve as a catalyst for further research and better treatments.”
The chief members of the organizing committee for The Summit include, Harold R. Collard, MD (Committee Chair); Zoë D. Bubany; Gregory P. Cosgrove MD; Kevin R. Flaherty MD, MS; Susan S. Jacobs, RN, MS; Dolly Kervitsky, CRT, CCRC; David J. Lederer MD, MS; Kathleen O. Lindell, PhD, RN; Jesse Roman MD; Daniel M. Rose, MD; Chris D. Schumann, MS, RCEP, CES; Jeffrey J. Swigris, MD; and Patti Tuomey, EdD.
Dr. Collard concluded by saying, “This is the third PFF Summit since 2011, and I’m not aware of another event that so successfully joins all the stakeholders to promote the science and clinical care of patients with pulmonary fibrosis. Customized breakout sessions intermixed with conference-wide plenary sessions will set the stage for audience participation and interaction among all attendees.”